TITLE

Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder

AUTHOR(S)
Lipkovich, Ilya; Jacobson, Jennie G.; Hardy, Thomas A.; Hoffmann, Vicki Poole
PUB. DATE
January 2008
SOURCE
BMC Psychiatry;2008, Vol. 8, Special section p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: To make well informed treatment decisions for their patients, clinicians need credible information about potential risk for substantial weight gain. We therefore conducted a post-hoc analysis of clinical trial data, examining early weight gain as a predictor of later substantial weight gain. Methods: Data from 669 (Study 1) and 102 (Study 2) olanzapine-treated patients diagnosed with schizophrenia, schizophreniform, or schizoaffective disorder were analyzed to identify and validate weight gain cut-offs at Weeks 1-4 that were predictive of substantial weight gain (defined as an increase of ≥ 5, 7, 10 kg or 7% of baseline weight) after approximately 30 weeks of treatment. Baseline characteristics alone, baseline characteristics plus weight change from baseline to Weeks 1, 2, 3 or 4, and weight change from baseline to Weeks 1, 2, 3, or 4 alone were evaluated as predictors of substantial weight gain. Similar analyses were performed to determine BMI increase cut-offs at Weeks 1-4 of treatment that were predictive of substantial increase in BMI (1, 2 or 3 kg/m² increase from baseline). Results: At Weeks 1 and 2, predictions based on early weight gain plus baseline characteristics were more robust than those based on early weight gain alone. However, by Weeks 3 and 4, there was little difference between the operating characteristics associated with these two sets of predictors. The positive predictive values ranged from 30.1% to 73.5%, while the negative predictive values ranged from 58.1% to 89.0%. Predictions based on early BMI increase plus baseline characteristics were not uniformly more robust at any time compared to those based on early BMI increase alone. The positive predictive values ranged from 38.3% to 83.5%, while negative predictive values ranged from 42.1% to 84.7%. For analyses of both early weight gain and early BMI increase, results for the validation dataset were similar to those observed in the primary dataset. Conclusion: Results from these analyses can be used by clinicians to evaluate risk of substantial weight gain or BMI increase for individual patients. For instance, negative predictive values based on data from these studies suggest approximately 88% of patients who gain less than 2 kg by Week 3 will gain less than 10 kg after 26-34 weeks of olanzapine treatment. Analysis of changes in BMI suggests that approximately 84% of patients who gain less than .64 kg/m² in BMI by Week 3 will gain less than 3 kg/m² in BMI after 26-34 weeks of olanzapine treatment. Further research in larger patient populations for longer periods is necessary to confirm these results.
ACCESSION #
35702837

 

Related Articles

  • Metformin for Prevention of Weight Gain and Insulin Resistance With Olanzapine: A Double-Blind Placebo-Controlled Trial. Baptista, Trino; Martínez, Jessan; Lacruz, Anny; Rangel, Nairy; Beaulie, Serge; Serrano, Ana; Arapé, Yinet; Martinez, Maritza; de Mendoza, Soaira; Teneud, Luis; Hernández, Luis // Canadian Journal of Psychiatry;Mar2006, Vol. 51 Issue 3, p192 

    Objective: To assess whether metformin prevents body weight gain (BWG) and metabolic dysfunction in patients with schizophrenia who are treated with olanzapine. Method: Forty patients taking olanzapine (10 mg daily) were randomly allocated to a metformin (n = 20; 850 to 1700 mg daily) or placebo...

  • Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder. Stauffer, Virginia L.; Sniadecki, Jennifer L.; Piezer, Kevin W.; Gatz, Jennifer; Kollack-Walker, Sara; Hoffmann, Vicki Poole; Conley, Robert; Durell, Todd // BMC Psychiatry;2010, Vol. 10, p89 

    Background: To examine potential differences in efficacy and safety of treatment with olanzapine in patients with schizophrenia of white and black descent. Methods: A post-hoc, pooled analysis of 6 randomized, double-blind trials in the treatment of schizophrenia, schizophreniform disorder, or...

  • BDNF Levels and Genotype are Associated with Antipsychotic-Induced Weight Gain in Patients with Chronic Schizophrenia. Xiang Yang Zhang; Dong Feng Zhou; Gui Ying Wu; Lian Yuan Cao; Yun Long Tan; Haile, Colin N.; Li, Jun; Lin Lu; Kosten, Therese A.; Kosten, Thomas R. // Neuropsychopharmacology;Sep2008, Vol. 33 Issue 10, p2200 

    Recent evidence suggests that centrally released brain-derived neurotrophic factor (BDNF) modulates eating behavior and metabolism that is responsible for body weight fluctuation. BDNF also may play an important role in the therapeutic action of antipsychotic medications. We investigated whether...

  • Individual dietary education reduces olanzapine associated weight gain. Evans, S.; Newton, R.; Higgins, S. // Evidence Based Mental Health;Feb2006, Vol. 9 Issue 1, p11 

    The article reports on a study showing that individual dietary education delivered by a dietitian reduces weight gain in people beginning olanzapine treatment. The results of the follow up of the study after three months were not reported due to high loss to follow up. Individual dietary...

  • Factors associated with early response to olanzapine and clinical and functional outcomes of early responders treated for schizophrenia in the People's Republic of China. Wenyu Ye; Montgomery, William; Kadziola, Zbigniew; Li Liu; Haibo Xue; Stensland, Michael D.; Treuer, Tamas // Neuropsychiatric Disease & Treatment;2014, Vol. 10, p869 

    Background: The aims of this analysis were to identify factors associated with early response (at 4 weeks) to olanzapine treatment and to assess whether early response is associated with better longer-term outcomes for patients with schizophrenia in the People's Republic of China. Methods: A...

  • Gaining weight for three. FAULKNER, JEANNE // Fit Pregnancy;Aug/Sep2011, Vol. 18 Issue 3, p124 

    The article reports on updated weight-gain guidelines from the U.S. Institute of Medicine for women pregnant with twins, which are based on the prepregnancy Body Mass Index (BMI) of the pregnant woman.

  • Do You Need To Lose Weight?  // Healthy Hearts, Healthy Homes - Do You Need to Lose Weight?;2008, preceding p1 

    This publication discusses the health benefits of weight loss. It discusses the reasons of weight gain and offers step-by-step instructions on how to identify if one needs to lose weight. A diagram showing the Body Mass Index (BMI) is shown. It also offers tips on how to lose unwanted weight. It...

  • AVOID POST-BABY WEIGHT GAIN. S. R. // Fit Pregnancy;Oct/Nov2011, Vol. 18 Issue 4, p32 

    The article offers information on the study conducted, which revealed the role played by body mass index (BMI) in reducing the post-pregnancy weight gain.

  • Weight Gain Among Men and Women College Students.  // Women in Academia Report;10/16/2012, p8 

    The article presents a study on the association between weight gain and body mass index of college students by the Auburn University.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics